Cordis acquires LuMend
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson/Cordis Corp. will complement its endovascular portfolio with LuMend's Outback LTD reentry catheter and its Frontrunner XP CTO for use in minimally invasive procedures such as angioplasty and stenting. Cordis is banking on the Sept. 28-announced acquisition of the Redwood City, Calif.-based company to augment its presence in chronic total occlusions treatment...
You may also be interested in...
Cordis updates catheters
Johnson & Johnson subsidiary introduces May 31 its Frontrunner XP CTO and Outback LTD re-entry catheters nationwide to treat lower leg artery blockages. Frontrunner is designed to cross through tough lesions with a jaw-like mechanism to allow balloons or stents to pass, while Outback helps redirect guidewires into the correct path through the plaque. The devices previously were marketed on a smaller scale by Lumend, which Cordis acquired last September (1"The Gray Sheet" Oct. 3, 2005, In Brief). Since the acquisition, Cordis has been ramping up production, as well as making device modifications. Frontrunner is tailored for peripheral use, with more sizes and a stronger radial force. The Cordis version of Outback includes a sharper needle tip and a locking mechanism on the deployment system. The revisions have improved the re-entry success rate with the device from 75% to 94%, according to the firm...
Firms Face Uphill Battle To Break Open Chronic Total Occlusion Market
Despite recent advances in specialized guidewires, industry has struggled to develop effective new technologies to aid in opening coronary chronic total occlusions, according to interventionalists
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.